Patents by Inventor Gertrud Hotten
Gertrud Hotten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7811793Abstract: A process for preparing a purified refolded monomer or dimer of a bone-derived factor, which comprises subjecting an inclusion body of a bone-derived factor produced by genetic engineering to the following steps a) to c) in sequence: a) introducing a polynucleotide encoding a bone morphogenetic factor into a bacterium, expressing said bone morphogenetic factor in the form of an inclusion body, recovering said inclusion body and treating it with a denaturing agent to obtain a solubilized monomer, b) treating the solubilized monomer without purification directly with a refolding solution to obtain a refolded monomeric bone morphogenetic factor, c) subjecting the refolded monomeric bone morphogenetic factor to purification.Type: GrantFiled: December 15, 2003Date of Patent: October 12, 2010Assignee: Biopharma Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka MBHInventors: Hidetoshi Andou, Jun Honda, Shunjiro Sugimoto, Gertrud Hötten, Rolf Bechtold, Jens Pohl
-
Patent number: 7632808Abstract: The present invention concerns the use of biologically active MP52 or/and MP121 for the treatment and prevention of diseases of the nervous system or/and for the treatment of neuropathological situations which are caused by ageing of the nervous system. A pharmaceutical agent according to the invention for the treatment and prevention of diseases of the nervous system or/and for treating neuropathological situations which are caused by ageing of the nervous system therefore contains biologically active MP52 or/and MP121 as the active substance.Type: GrantFiled: February 3, 2003Date of Patent: December 15, 2009Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von PharmakaInventors: Gertrud Hötten, Jens Pohl, Rolf Bechtold, Michael Paulista, Klaus Unsicker
-
Patent number: 7569227Abstract: The present invention is concerned with proteins selected from the members of the TGF-? superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation. The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.Type: GrantFiled: July 28, 2005Date of Patent: August 4, 2009Assignee: HyGene AGInventors: Gertrud Hötten, Rolf Bechtold, Jens Pohl
-
Patent number: 7141239Abstract: The invention provides DNA sequences encoding novel members of the TGF-? family of proteins. The TGF-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.Type: GrantFiled: April 14, 2005Date of Patent: November 28, 2006Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl
-
Patent number: 7129054Abstract: The invention relates to an antibody or antibody fragment which specifically binds to a protein of the TGF-? family. The invention also relates to a kit for detecting a protein of the TGF-? family which comprises the antibody or antibody fragment. Finally, the invention relates to method for detecting a protein of the TGF-? family which uses the antibody or antibody fragment.Type: GrantFiled: May 19, 2005Date of Patent: October 31, 2006Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista
-
Patent number: 7067637Abstract: The invention provides antibody and antibody fragments which specifically bind to novel members of the TGF-? family of proteins. The TFG-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also applies to the production of said antibodies or antibody fragments and a diagnostic method for detecting said proteins of the TGF-? family.Type: GrantFiled: September 24, 1999Date of Patent: June 27, 2006Assignee: BioPharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt
-
Patent number: 7025959Abstract: The invention concerns a protein of the TGF-? family, the DNA coding therefor and a pharmaceutical composition containing such protein.Type: GrantFiled: October 10, 2000Date of Patent: April 11, 2006Assignee: Biopharm Gesellschaft Zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista
-
Publication number: 20050282255Abstract: The present invention is concerned with proteins selected from the members of the TGF-? superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation. The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.Type: ApplicationFiled: July 28, 2005Publication date: December 22, 2005Applicant: HyGene AGInventors: Gertrud Hotten, Rolf Bechtold, Jens Pohl
-
Patent number: 6972321Abstract: The present invention is concerned with proteins selected from the members of the TGF-? superfamily, which are monomeric due to substitution or deletion of a cystein which is responsible for dimer formation. The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The pharmaceutical compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.Type: GrantFiled: August 4, 2000Date of Patent: December 6, 2005Assignee: HyGene AGInventors: Gertrud Hötten, Rolf Bechtold, Jens Pohl
-
Publication number: 20050220794Abstract: The invention relates to an antibody or antibody fragment which specifically binds to a protein of the TGF-? family. The invention also relates to a kit for detecting a protein of the TGF-? family which comprises the antibody or antibody fragment. Finally, the invention relates to method for detecting a protein of the TGF-? family which uses the antibody or antibody fragment.Type: ApplicationFiled: May 19, 2005Publication date: October 6, 2005Applicant: Biopharm Gesellschaft zurInventors: Gertrud Hotten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista
-
Publication number: 20050175553Abstract: The invention provides DNA sequences encoding novel members of the TGF-? family of proteins. The TGF-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.Type: ApplicationFiled: April 14, 2005Publication date: August 11, 2005Applicant: BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBHInventors: Gertrud Hotten, Helge Neidhardt, Rolf Bechtold, Jens Pohl
-
Publication number: 20050026247Abstract: A process for preparing a purified refolded monomer or dimer of a bone-derived factor, which comprises subjecting an inclusion body of a bone-derived factor produced by genetic engineering to the following steps a) to c) in sequence: a) introducing a polynucleotide encoding a bone morphogenetic factor into a bacterium, expressing said bone morphogenetic factor in the form of an inclusion body, recovering said inclusion body and treating it with a denaturing agent to obtain a solubilized monomer, b) treating the solubilized monomer without purification directly with a refolding solution to obtain a refolded monomeric bone morphogenetic factor, c) subjecting the refolded monomeric bone morphogenetic factor to purification.Type: ApplicationFiled: December 15, 2003Publication date: February 3, 2005Applicant: Biopharma Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka GmbHInventors: Hidetoshi Andou, Jun Honda, Shunjiro Sugimoto, Gertrud Hotten, Rolf Bechtold, Jens Pohl
-
Publication number: 20040146979Abstract: The invention concerns a protein of the TGF-&bgr; family, the DNA coding therefor and a pharmaceutical composition containing the protein.Type: ApplicationFiled: March 16, 2004Publication date: July 29, 2004Applicant: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hotten, Helge Neidhardt, Michael Paulista
-
Patent number: 6764994Abstract: The invention concerns a protein of the TGF-&bgr; family, the DNA coding therefor and a pharmaceutical composition containing the protein.Type: GrantFiled: August 31, 1999Date of Patent: July 20, 2004Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Michael Paulista
-
Publication number: 20040019185Abstract: A process for preparing a purified refolded monomer or dimer of a bone-derived factor, which comprises subjecting an inclusion body of a bone-derived factor produced by genetic engineering to the following steps a) to c) in sequence:Type: ApplicationFiled: April 16, 2003Publication date: January 29, 2004Inventors: Hidetoshi Andou, Jun Honda, Shunjiro Sugimoto, Gertrud Hotten, Rolf Bechtold, Jens Pohl
-
Publication number: 20030220248Abstract: The present invention concerns the use of biologically active MP52 or/and MP121 for the treatment and prevention of diseases of the nervous system or/and for the treatment of neuropathological situations which are caused by ageing of the nervous system. A pharmaceutical agent according to the invention for the treatment and prevention of diseases of the nervous system or/and for treating neuropathological situations which are caused by ageing of the nervous system therefore contains biologically active MP52 or/and MP121 as the active substance.Type: ApplicationFiled: February 3, 2003Publication date: November 27, 2003Inventors: Gertrud Hotten, Jens Pohl, Rolf Bechtold, Michael Paulista, Klaus Unsicker
-
Patent number: 6531450Abstract: The present invention concerns the use of biologically active MP52 or/and MP121 for the treatment and prevention of diseases of the nervous system or/and for the treatment of neuropathological situations which are caused by ageing of the nervous system. A pharmaceutical agent according to the invention for the treatment and prevention of diseases of the nervous system or/and for treating neuropathological situations which are caused by ageing of the nervous system therefore contains biologically active MP52 or/and MP121 as the active substance.Type: GrantFiled: May 18, 1998Date of Patent: March 11, 2003Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von PharmakaInventors: Gertrud Hötten, Jens Pohl, Rolf Bechtold, Michael Paulista, Klaus Unsicker
-
Publication number: 20020045568Abstract: The present invention concerns the use of biologically active MP52 or/and MP121 for the treatment and prevention of diseases of the nervous system or/and for the treatment of neuropathological situations which are caused by ageing of the nervous system. A pharmaceutical agent according to the invention for the treatment and prevention of diseases of the nervous system or/and for treating neuropathological situations which are caused by ageing of the nervous system therefore contains biologically active MP52 or/and MP121 as the active substance.Type: ApplicationFiled: May 18, 1998Publication date: April 18, 2002Inventors: GERTRUD HOTTEN, JENS POHL, ROLF BECHTOLD, MICHAEL PAULISTA, KLAUS UNSICKER
-
Patent number: 6197550Abstract: The invention provides DNA sequences encoding novel members of the TGF-&bgr; family of proteins. The TGF-&bgr; family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.Type: GrantFiled: April 3, 1998Date of Patent: March 6, 2001Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharamaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl
-
Patent number: 6171584Abstract: The invention concerns a protein of the TGF-&bgr; family, the DNA coding therefor and a pharmaceutical composition containing such protein.Type: GrantFiled: December 22, 1998Date of Patent: January 9, 2001Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista